Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,059 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,059 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without… | Phase 2 | terminated | Nov 24, 2014 | Pfizer | The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development.… | Safety / toxicity |
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Nov 6, 2012 | Eli Lilly and Company | Change in clinical strategy. | Sponsor / business decision |
| NCT03334487 | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment… | Phase 3 | withdrawn | Nov 7, 2017 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02788578 | A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for…(PRELUDE) | — | terminated | Jun 2, 2016 | Ipsen | The study terminated prematurely due to insufficient recruitment. | Enrollment / accrual |
| NCT02026960 | RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal… | N/A | terminated | Jan 3, 2014 | Duke University | The sponsor's clinical program for the agent used in this study was discontinued. | Other (stated, no rule matched) |
| NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With… | Phase 2 | terminated | Apr 17, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low enrollment | Enrollment / accrual |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro… | Phase 2 | terminated | Aug 11, 2017 | HiberCell, Inc. | Due to enrollment challenges resulting in changing treatment patterns, the study has been… | Enrollment / accrual |
| NCT01740154 | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer | N/A | terminated | Dec 4, 2012 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01912963 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With… | Phase 2 | terminated | Jul 31, 2013 | Dana-Farber Cancer Institute | The study terminated early due to weak accrual. | Enrollment / accrual |
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Oct 10, 2012 | University of Washington | Closed 2017 for low accrual. Last data for primary outcome on 02Feb2015. | Enrollment / accrual |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome… | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual,primary endpoint reached \& investigator left NIH. | Investigator |
| NCT03366675 | AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] | Phase 2 | terminated | Dec 8, 2017 | Samsung Medical Center | Early detection of the purpose of the study. | Other (stated, no rule matched) |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or… | Phase 3 | withdrawn | Oct 3, 2018 | Hoffmann-La Roche | In the context of the ongoing evaluation of our data, we have determined that there is no need to… | Safety / toxicity |
| NCT01764607 | Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | Phase 2 | terminated | Jan 9, 2013 | University of Florida | Poor accrual | Enrollment / accrual |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination…(RENALVax-2) | Phase 2 | withdrawn | Jul 21, 2017 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | No patients enrolled due to change in standard practice | Enrollment / accrual |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein… | Phase 1 / Phase 2 | terminated | Jan 27, 2017 | Taiwan Liposome Company | Current study design couldn't support futher development on this indication. | Other (stated, no rule matched) |
| NCT03527784 | Prestoma-Trial for Parastomal Hernia Prevention | N/A | terminated | May 17, 2018 | University of Oulu | Parastomal Parietex withdrawn from market by the manufacturer. | Drug supply |
| NCT02868892 | A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas | Phase 2 | terminated | Aug 16, 2016 | Western Regional Medical Center | departure of PI from institution and poor population for study participation | Other (stated, no rule matched) |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment… | Phase 2 | terminated | Jul 21, 2017 | National Cancer Institute (NCI) | Principal Investigator left the NIH. | Investigator |
| NCT00672009 | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | Phase 2 | terminated | May 6, 2008 | Cedars-Sinai Medical Center | The sponsor terminated funding for the study. | Funding |
| NCT00702962 | Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive… | Phase 1 / Phase 2 | terminated | Jun 20, 2008 | Milton S. Hershey Medical Center | Poor accrual | Enrollment / accrual |
| NCT02787954 | Prospective Tumor Response Evaluation(Liver) | — | terminated | Jun 1, 2016 | The University of Texas Health Science Center, Houston | PI transferred to another institution and did not take this study with him. | Other (stated, no rule matched) |
| NCT02234180 | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or… | Phase 2 | terminated | Sep 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Phase 2 | terminated | Sep 25, 2015 | The University of Texas Health Science Center, Houston | Loss of laboratory performing molecular analysis | Other (stated, no rule matched) |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus… | Phase 2 | withdrawn | May 5, 2016 | Bristol-Myers Squibb | Insufficient enrollment | Enrollment / accrual |
| NCT02500914 | SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma | Phase 1 | terminated | Jul 17, 2015 | Stemcentrx | Strategic Considerations | Sponsor / business decision |
| NCT03358004 | the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or…(VICTOR3) | Phase 2 | terminated | Nov 30, 2017 | Mario Negri Institute for Pharmacological Research | Low accrual rate | Enrollment / accrual |
| NCT01795365 | Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer | N/A | terminated | Feb 20, 2013 | Centre Hospitalier Universitaire Vaudois | Participants are no longer being examined and receiving intervention. | Other (stated, no rule matched) |
| NCT02599909 | Gut Microbiota in People With Hepatocellular Carcinoma (HCC) | — | withdrawn | Nov 9, 2015 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02688907 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer… | Phase 2 | terminated | Feb 23, 2016 | Samsung Medical Center | change regimen | Other (stated, no rule matched) |
| NCT03106155 | Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring…([SUKSES-D]) | Phase 2 | terminated | Apr 10, 2017 | Samsung Medical Center | Decision of IP support organization | Other (stated, no rule matched) |
| NCT02967523 | Surefire Precision Infusion System Registry | — | terminated | Nov 18, 2016 | Surefire Medical, Inc. | not stated | Not stated |
| NCT03345225 | A Clinical Study of Precision TACE (P-TACE) With Surefire | N/A | withdrawn | Nov 17, 2017 | University of Miami | Funding | Funding |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT01425996 | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced… | Phase 1 / Phase 2 | terminated | Aug 30, 2011 | Taiwan Liposome Company | not stated | Not stated |
| NCT02750033 | Intraoperative Margin Assessment During Mohs Surgery | — | withdrawn | Apr 25, 2016 | Seton Healthcare Family | Protocol changed to meet IRB requirements for patient safety | Safety / toxicity |
| NCT00527124 | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic… | Phase 2 | terminated | Sep 10, 2007 | National Cancer Institute (NCI) | Closure was recommended by CTEP due to slow accrual. | Enrollment / accrual |
| NCT01642095 | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | — | withdrawn | Jul 17, 2012 | Children's Oncology Group | not stated | Not stated |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative… | Phase 1 / Phase 2 | terminated | Nov 26, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Slow accrual and high levels of toxicity lead to early termination. | Safety / toxicity |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell… | Phase 1 | terminated | Mar 11, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus… | Phase 2 | terminated | May 13, 2013 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00488384 | Acitretin Plasma Levels Under Hemodialysis | Phase 4 | withdrawn | Jun 20, 2007 | Günther Hofbauer | lack of subjects | Other (stated, no rule matched) |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | National Cancer Institute (NCI) | The study itself was Disapproved on 04/20/2018 and will not be moving forward. | Other (stated, no rule matched) |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and… | Phase 2 | terminated | Aug 13, 2013 | Radiation Therapy Oncology Group | Trial would not be completed in a reasonable timeframe per CTEP guidelines | Other (stated, no rule matched) |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | Phase 2 | terminated | Jan 26, 2015 | Case Comprehensive Cancer Center | Competing studies | Other (stated, no rule matched) |
| NCT02943603 | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially… | Phase 2 | withdrawn | Oct 24, 2016 | Weijing Sun, MD, FACP | No participants enrolled. PI/Sponsor left UPitt. IND withdrawn \& revised protocol submitted… | Enrollment / accrual |
| NCT02491411 | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With…(DEXTER) | N/A | terminated | Jul 8, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study is terminated due to lower enrollment | Enrollment / accrual |
| NCT02057874 | 3-Tesla MRI Response to TACE in HCC (Liver Cancer) | N/A | terminated | Feb 7, 2014 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT02011087 | Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With… | N/A | terminated | Dec 13, 2013 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 8, 2019source: clinicaltrials